company presentation - biogaia
Post on 15-Apr-2022
4 Views
Preview:
TRANSCRIPT
Company presentation
BioGaia in short
2
555 patents in 30 families
Listed on Nasdaq Stockholm (mid cap list)
Products in more than 100 markets
Offices in Sweden (Stockholm, Lund, Eslöv, Gothenburg), Singapore, USA, Japan, South Africa
160 employees
Founded in 1990
555
Three subsidiaries (BioGaia Production, BioGaia Pharma, MetaboGen)
To be the ground-breaking leader in probiotics that contributes to improved health by educating people and
providing probiotic products for defined indications
OUR MISSION
4
30 years of probiotic innovation
Founded by Peter
Rothschild and Jan Annwall
Listed on Nasdaq
Stockholm
BioGaialaunches
world’s first probiotic chewable
tabletAgreement with
Ascendis (South Africa)
BioGaia Production is formed
Agreement with Nóos
(Italy)
BioGaia launches
world’s first probiotic
dropsAgreement
with Verman(Finland)
Agreement with
EwopharmaAG (Eastern
Europe)Agreement with Ferring
(Middle East)
BioGaiaJapan
founded
First agreement with Nestlé
Agreement with Abbott (LatAm &
Asia)BioGaia
invests in MetaboGen
1998 2002 20061990 2000 2003 20082004 2014 2017
BioGaiasets up
subsidiary BioGaiaPharma
2018
BioGaia sets up The
Foundation to Prevent Antibiotic
Resistance
5
BioGaia has a unique business model
Flexible business model
NETWORKResearchers
Preclinical and clinicalstudies at hospitals
and universities
BioGaiaProduct development
Product strategiesResearch
Quality assurance systemMarketing support
IP
NETWORKSuppliers
Production andpackaging
NETWORKPartners
Pharmaceutical orhealthcare companies
with sales organizations
BioGaia
Universities and hospitals where research is conducted
Manufacturing andpackaging units
Partners with salesof products
BioGaia business model
• Developing products sold around the world via a network of distribution partners
• Building a strong brand towards healthcare professionals and consumers
7
8
• More than 70 countries
• >70% of sales of finished consumer products*
• Build value, less dependence on patents
BioGaia brand
* BioGaia brand incl co-branding
224
18,000
…clinical studies. Results published in scientific journals
All BioGaia probiotics areclinically proven
* Previously known as Lactobacillus
…individuals of all ages have taken part in clinical studies
with BioGaia’s human strains of Limosilactobacillus* reuteri
10
BioGaia focus areas
11
Stay HealthyMother & Child
12
Mother & Child
INFANCYColic,
Infection Protection
BIRTHAASE*, C-section, Infection Protection
PREGNANCYInfection Protection,
AASE*, Constipation, Gingivitis
*Antibiotic associated side-effects**Functional Abdominal Pain
BioGaia focuses on prevention and treatment during pregnancy, in infancy and throughout childhood.
CHILDHOODFAP**, AASE*,
Constipation, Acute Gastroenteritis
13
Mother & ChildBIRTH
AASE*, C-section, Infection Protection
*Antibiotic associated side-effects**Functional Abdominal Pain
BioGaia focuses on prevention and treatment during pregnancy, in infancy and throughout childhood.
INFECTION PROTECTION
Strengthen immune system
BONE HEALTHBone loss
(osteopenia)
ORAL HEALTHPeriodontal disease
GUT HEALTHGut motility
Gut inflammation
BioGaia focuses on prevention of age-related conditions and maintenance of general well-being
Stay Healthy
BioGaia focuses on prevention of age-related conditions and maintenance of general well-being
Stay Healthy
16
Sustainability a part of BioGaia’s DNA
Sustainability framework
Sustainable packaging
Sustainable raw materials
Transparent and robust science
Product quality and safety
Responsible partners
Responsible suppliers
Responsible research
The Foundation to Prevent Antibiotic Resistance
Children's MissionFriends of PanziClimate Offset
Healthy networks
Health & wellbeing
Training & development
Safety in production
Healthy workplace Healthy business Healthy products
Investments for global health
Business ethics
Climate change
Environmental impact in production
Intellectual property
18
The global probiotics market
Increasing out-of-pocket healthcare expenditure
19
0
200
400
600
800
1000
1200
1970
1972
1974
1976
1978
1980
1982
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
2010
2012
2014
2016
2018
USD
AUS
FRA
IND
JPN
MEX
SWE
USA
Source: OECD 2019
20Source: Euromonitor 2019
0
1 000
2 000
3 000
4 000
5 000
6 000
7 000
8 000
9 000
10 000
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019202
0F202
1F202
2F202
3F202
4F
Mar
ket v
alue
(USD
m)
4.3%
5.7%
Global probiotic market estimated to grow by CAGR 4-5%
11.4%
8.7%
• Growing interest in health
• Sustainable companies are winners
• Antibiotic resistance is a growing threat
• High growth opportunities in APAC region
• Increased access through growing online channel and e-commerce players
Market trends point towards probiotics
21
BioGaia Group – The Microbiome Partner
BioGaia Group organisation
22(Number of employees)
BioGaia Production and Centre of Excellence
• Production of BioGaia drops, easydropper, minipack and samples
• GMP pharma certified
• Centre of Excellence – D&R and Product development • Small-scale trials and small-scale production• Test and analyse raw material and finished products• Discover and develop understanding of current and new bacterial strains
23
Development of next generation probiotics
• Develop products from novel anaerobic strains, derived from the human gut but not previously used as probiotics, targeted for precise indications
• Food supplements or drugs• Evaluating potential probiotic strains by
metagenomic technologies and metabolic modelling
• In-house development of unique technology for production of products with anaerobic strains
• Strain development, small-scale production and clinical study preparation performed in highly specialised facilities outside Gothenburg
• First product in clinical phase
Pipeline
Metabolic disease (NAFLD, prediabetes)• Two-strain combination• Safety study completed• Efficacy study to be performed 2021
Intrahepatic Cholestasis in Pregnancy (ICP)• Exploratory study completed• In partnership with Ferring Pharmaceuticals
Immunotherapy in melanoma• Prospective study ongoing• Goal: companion product to improve response to treatment with current drugs
top related